Stockreport

OnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business Update

OnKure Therapeutics, Inc. - Class A  (OKUR) 
PDF -- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in combination with fulvestrant and ribociclib, and in combination with tras [Read more]